In these 14 Member States, therefore, it is unclear for patients exactly which treatments are subject to prior authorisation, since the use of at least one of these criteria - and sometimes both - has not been elucidated by national authorities.
Neis 14 liikmesriigis on patsientide jaoks siiski ebaselge, millise ravi puhul on eelluba nõutav, sest riigi ametiasutused ei ole vähemalt ühe ja vahel ka kummagi kriteeriumi kasutamist selgitanud.